论文部分内容阅读
目的:评价甲基强的松龙用于治疗慢肝的急性肝衰竭患者的临床疗效和安全性。方法:选取2012年1月—2014年1月间收治的慢肝的急性肝衰竭患者患者86例,将其分为观察组(n=43)与对照组(n=43);对照组患者均给予常规综合治疗,观察组患者对照组常规综合治疗的基础上均给予短程甲基强的松龙冲击治疗,比较两组患者治疗后的肝功能恢复情况、总有效率、6月生存率和平均住院时间、住院费用以及严重并发症的发生率等相关指标的变化情况。结果:观察组患者接受短程甲基强的松龙冲击治疗后的总有效率和6月生存率明显均优于对照组(P<0.05);而严重并发症的发生率则显著低于对照组(P<0.05);平均住院时间和住院费用也显著少于对照组(P<0.05)。结论:合理使用甲基强的松龙治疗慢肝的急性肝衰竭患者患者,且临床疗效较为显著。
Objective: To evaluate the clinical efficacy and safety of methylprednisolone for the treatment of acute liver failure in chronic liver disease. Methods: Totally 86 patients with chronic liver failure who were admitted to our hospital from January 2012 to January 2014 were divided into the observation group (n = 43) and the control group (n = 43). The patients in the control group The patients in the observation group were given conventional methylprednisolone impact therapy on the basis of conventional comprehensive treatment. The recovery of liver function, total effective rate, 6-month survival rate and average Length of stay, cost of hospitalization and the incidence of serious complications and other related indicators of changes. Results: The total effective rate and survival rate of patients in observation group after receiving short-acting methylprednisolone shock treatment were significantly better than those of control group (P <0.05), while the incidence of serious complications was significantly lower than that of control group (P <0.05). The average length of hospital stay and hospitalization cost were also significantly less than those of the control group (P <0.05). Conclusion: The rational use of methylprednisolone in patients with chronic liver failure in patients with chronic liver disease, and the clinical efficacy is more significant.